Multiomics Market Research Report Information By Product & Service (Products, [Instruments, Consumables, Software], and Services), By Type (Bulk Multiomics and Single-cell Multiomics), By Platform (Genomics, Metabolomics, Proteomics, Transcriptomics, and Integrated Omics Platforms), By Application (Cell Biology, Oncology, Immunology, and Neurology), By End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast

Global Multiomics Market Overview

Multiomics Size was valued at USD 2.1 Billion in 2022. The Multiomics market industry is projected to grow from USD 2.4 Billion in 2023 to USD 7.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.60% during the forecast period (2024 - 2032). Increasing demand for personalized medicine and growing advancements in omics technologies are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Multiomics Market Trends

• Rising integration of multi-omics data is driving the market growth

The multiomics market CAGR is experiencing substantial growth in the recent years. Biological systems can be seen holistically when data from several omics layers, including transcriptomics, proteomics, metabolomics, and genomes, are integrated. The advent of this thorough comprehension propels the need for multiomics services and technology by allowing researchers to unearth intricate disease mechanisms, regulatory networks, and molecular connections. Developing novel disease biomarkers, therapeutic targets, and diagnostic signs is easier through the integrated analysis of multiomics data. Researchers can clarify disease pathways and pinpoint possible targets for drug development and precision medicine applications by establishing a correlation between genetic variants and changes in gene expression, protein abundance, and metabolic profiles. Molecular profile-based individualized healthcare interventions are made possible by integrating multiomics data. The need for multiomics-based diagnostics and treatments is driven by healthcare professionals' ability to enhance treatment methods, anticipate treatment responses, and reduce unwanted effects by merging genomic, transcriptomic, and other omics data with clinical information.

Introducing new, improved commercial multi-omics platforms mostly influences the multi-omics market's growth. Researchers are gaining deeper insights due to these new platforms, which provide integrated study of various biological data sets. Integrating many omics datasets, including transcriptomics, proteomics, metabolomics, and genomes, from a single sample offers a more thorough comprehension of biological systems and pathways. Businesses are launching platforms, for instance, that enable multi-omics analysis to be done at a scale and depth never seen before. Using their instruments, companies like Illumina can now analyze millions of cells simultaneously at single-cell resolution. This makes it possible for researchers to find even uncommon cell types and alterations in cellular states. Similarly, several platforms successfully integrate microscopy-based spatial profiling methods with multi-omics analysis.

The market demand is also anticipated to rise due to researchers' growing interest in single-cell genomics. The National Library of Medicine issued a study in March 2023 that states single-cell genomics offers numerous uses in studying cardiovascular disorders. It can be applied to heart development, atherosclerosis, atrial fibrillation, cardiac hypertrophy, myocardial infarction (MI), cardiac ischemia-reperfusion (I/R) injury, and heart failure.

Cardiovascular diseases (CVDs) may also benefit from new therapeutics made possible by single-cell genomics. Moreover, there is a notable rise in the prevalence of cardiovascular diseases. The American Heart Association estimates that 19.1 million individuals worldwide died from cardiovascular diseases (CVDs) in 2020. Therefore, it is anticipated that as CVDs rise, so will the need for single-cell genomics, propelling the market expansion and driving the Multiomics market revenue.

Multiomics Market Segment Insights

Multiomics Product & Service Insights

The Multiomics segmentation, based on Product & Service, includes products, [instruments, consumables, software], and services. In 2023, the products segment dominated the market. Instruments, consumables, and software are the other product categories. The market is predicted to rise due to the expanding innovations and product launches. Enterprises are establishing alliances to create innovative tools and platforms for studying and analyzing several omics. To develop a fully automated spatial multiomics solution, for example, Bio-Techne and Lunaphore worked together in April 2023. These advancements are expected to drive the segment's expansion throughout the projection period.

The services category is anticipated to be the fastest growing. Participants provide a wide range of multiomics-focused services in response to the growing demand. For instance, the multiomics contract research company Psomagen announced the availability of its Spatial Biology services in September 2023. Transcriptomics, genomics, and proteomics are just a few of the omics platforms integrated by this service. Thus, growing service offerings will propel the segment's growth in the coming years.

Multiomics Type Insights

Based on Types, the Multiomics segment includes bulk multiomics and single-cell multiomics. In 2023, the bulk multiomics category generated the most income. Bulk multiomics is typically required to systematically explain the pathophysiology of disorders and other phenotypes at the individual level. The dominance of this industry can be due to the multiple advantages of bulk multiomics. The straightforward experimental procedure and reasonably priced large-scale sample dissection are two benefits. Furthermore, live cells are not necessary for bulk multiomics techniques.

The single-cell multiomics segment is anticipated to grow fastest during the forecast period. The need for single-cell multiomics to comprehend intricate biological systems is thought to be the reason for the greater growth rate. Furthermore, the individuals involved are concentrating on these kinds of goods. For example, Mission Bio, Inc. unveiled the Tapestri Single-cell Multiomics Solution to develop precision cancer therapeutics in October 2020. This approach provides more information into therapy resistance and relapse by integrating two assays into a single platform. Over the projection period, such activities and product introductions are expected to accelerate the segment growth.

Multiomics Platform Insights

Based on Platform, the Multiomics segmentation includes genomics, metabolomics, proteomics, transcriptomics, and integrated omics platforms. The genomics category leads the market. The genomics sector has developed several cutting-edge products. Additionally, businesses are expanding the products and services they offer in this market, which helps to fuel the sector's expansion. For example, Google Cloud unveiled its AI-powered Multiomics Suite in May 2023. Precision therapy design and genetic data interpretation can benefit from this offering. Thus, launches that concentrate on interpreting genetic data are anticipated to propel category expansion

 throughout the forecast period.

The multiomics market’s metabolomics segment is anticipated to grow fastest during the projection period. This growth is anticipated to be driven by the rising incidence of cancer worldwide and the growing number of studies utilizing multiomics techniques for cancer research. According to a study released in February 2018, metabolomics is crucial to studying pancreatic cancer prognosis.

Multiomics Application Insights

The Multiomics segmentation, based on Application, includes cell biology, oncology, immunology, and neurology. The cell biology category leads the market. The application of multiomics techniques is transforming our knowledge of cellular biology in the context of health and illness. Furthermore, there are a plethora of resources available to comprehend cell biology. For example, two technologies that allow for single-cell multi-omic analysis were introduced by BioSkryb Genomics in February 2023. These goods can aid in the comprehension of cell biology through the use of multi-omic platforms.

The oncology segment of the multiomics market is predicted to develop quickly over the projected period. The market is expected to rise due to rising cancer incidence rates and the expanding value of multiomics for cancer treatment. Numerous initiatives are being taken by businesses and researchers to use multi-omic techniques to aid people living with cancer. For instance, the biotech startup Freenome initiated the Sanderson Study in September 2022, utilizing real-world data and its multiomics platform to detect certain malignancies.

Multiomics End User Insights